Expertise
Every practice starts the same way: name the decision, surface the assumptions underneath it, and build only the evidence that will move it. The methods change with the question. The discipline does not.
Economic evaluation & modeling
Decision-analytic models that payers, HTA bodies and public funders can interrogate line by line, from the societal or payer perspective and reported to CHEERS 2022.
What we do
- Cost-effectiveness and cost-utility analysis
- Budget-impact and scenario modeling
- Markov and decision-tree models
- Probabilistic and deterministic sensitivity analysis
- Forecasting and base-year cost standardization
- CHEERS 2022 and ISPOR good-practice reporting
In practice
- Public health · Cost-effectivenessWhat is a school inhaler worth?Read
- Biopharma · HTA & evidence strategyA Phase III program built for payers as well as regulatorsRead
Toolkit
- TreeAge Pro
- Excel / VBA
- R
- Stata
- SAS
HTA & market access strategy
From PICO scoping to Joint Clinical Assessment readiness, we map what each HTA body has accepted before, then build the evidence for each of them.
What we do
- Global value dossiers and evidence packages
- HTA precedent and threshold analysis across markets
- EU Joint Clinical Assessment readiness
- NICE, ICER, IQWiG, HAS, CADTH, PBAC and Japan C2H frameworks
- Comparator, positioning and indirect-comparison feasibility
- Evidence-gap and claim-boundary assessment
Clinical evidence & endpoint strategy
A trial can win approval and still stall at reimbursement. We design endpoint hierarchies and confirmatory evidence plans that serve labeling and HTA at the same time.
What we do
- Phase III endpoint hierarchy design
- PRO and COA selection: content validity, responsiveness, meaningful change
- Systematic and targeted literature review
- Meta-analysis
- Confirmatory evidence for FDA, EMA, MHRA, Health Canada, TGA and PMDA
Real-world evidence & AI-enabled phenotyping
Claims, surveys, surveillance feeds and clinical free text, combined into cohorts and burden estimates. When codes undercount a disease, we use NLP to find the missing patients.
What we do
- Medicaid claims, MarketScan, MEPS, BRFSS, HCUP, SEER and ESSENCE
- NLP phenotyping lexicons for EHR and pathology text
- Cohort design for treatment-pattern and progression studies
- Prevalence and burden-of-illness estimation
- Equity-stratified and geographic analysis
In practice
- AI · Real-world evidenceFinding the patients diagnosis codes missRead
- Public health · Cost-effectivenessWhat is a school inhaler worth?Read
Toolkit
- R
- Python
- SQL
- Stata
- QGIS
- Power BI
Pricing & health policy analysis
IRA negotiation, most-favored-nation pricing, tariffs and shifting HTA thresholds, each modeled as financial exposure and sequenced into a plan.
What we do
- Inflation Reduction Act negotiation exposure modeling
- Most-favored-nation pricing scenarios
- International HTA threshold and tariff-change briefings
- Medicaid coverage and reimbursement policy
- Likelihood-by-impact policy risk matrices
Public health program evaluation & strategy
CDC-grade evaluation designs, societal-perspective economics and strategic plans that a program, its partners and its funder can all measure progress against.
What we do
- Evaluation protocols, logic models and data plans
- Societal-perspective cost-effectiveness of public programs
- Strategic plans, measurement crosswalks and roadmaps
- Grant budget and funding-proposal advisory
- Methods workshops for agencies and coalitions
- Dashboards for state and federal stakeholders
Work with us
Most questions span more than one. Describe the decision and we will scope the evidence it needs. Nothing more.